Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma

BACKGROUND: Sorafenib was the first Food and Drug Administration approved anti-angiogenic therapy for renal cell carcinoma (RCC). Currently, there are no validated predictive biomarkers for sorafenib. Our purpose was to determine if sorafenib target expression is predictive of sorafenib sensitivity....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Aziz, Saadia A, Sznol, Joshua A, Albiges, Laurence, Zito, Christopher, Jilaveanu, Lucia B, Camp, Robert L, Escudier, Bernard, Kluger, Harriet M
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Primary Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3896780/
https://ncbi.nlm.nih.gov/pubmed/24423208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2867-14-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados